Refine by
Precision Medicine Articles & Analysis
237 news found
Additionally, exosome-loaded protein-based therapy is opening new doors for regenerative medicine, while limb occlusion research is enhancing vascular treatments. ...
Massimo Cristofanilli, a Professor of Medicine at Weill Cornell Medicine, and at Tethis, will focus on patients with early-stage breast cancer who are given drugs to reduce tumor size, prior to surgery to remove the tumors. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
The company has introduced a state-of-the-art approach to enhance the precision and efficiency of delivering therapeutic antibodies directly to targeted sites, aiming to boost therapeutic efficacy while reducing unwanted side effects. ...
The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio’s POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. ...
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. ...
ByTempus
This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision medicine. Epigenetics is a field of genetics that delves into the influence of chemical modifications within the genome ...
Shaochen Chen, a pioneer and expert in 3D printing and biofabrication, who has published extensively on bioprinting techniques for tissue engineering and regenerative medicine. The Centre of Excellence will provide researchers at UCSD and beyond with increased access to CELLINK bioprinting technologies and support their efforts to develop innovative solutions to address some of ...
ByCELLINK
Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. ...
This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge protein drug design. ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
HLA typing, the process of identifying specific alleles within the HLA genes, is indispensable for personalized medicine, disease association studies, and achieving successful transplant outcomes. ...
CD Genomics' Viral Metagenomic Sequencing service empowers researchers and public health officials to identify emerging pathogens, monitor viral evolution, and enable precision medicine. In the clinical setting, rapid and accurate diagnosis is paramount to effective patient management. ...
"LAA breaks through traditional sequencing constraints, empowering researchers with invaluable insights into the most intricate areas of the genome, accelerating their research and making significant contributions to diverse fields, including cancer research, microbiome studies, and precision medicine." CD Genomics' LAA service is fortified by a team of expert ...
This cutting-edge technology offers exceptional accuracy and long-read capabilities, enabling researchers to reconstruct full-length transcripts with precision, facilitating in-depth investigations into gene function and regulatory mechanisms. ...
This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise genetic information plays a pivotal role. ...
These polymers help researchers overcome a variety of obstacles such as lengthy chemical synthesis and purification, limited material selection for additive manufacturing precision medicine, unpredictable or uncontrollable degradation rates of drug-carrying cargoes, and denaturation of biomolecules during binding. Together with these biodegradable polymers, this ...